Professor, Internal Medicine, University of Virginia School of Medicine
Endocrinology
Dr. Richard J. Santen, MD
|
|
Give Review
Richard J. Santen, MD practices Endocrinology. He attended University of Michigan Medical School. He received awards:"CMS Meaningful Use Stage 1 Certification" and "Elected Member". Doctor Richard J. Santen, MD is a published physician. He has 59 publications published. The most current publication "Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline." Richard Santen accepts Medicare.
Publications
- Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline.
- Adenosine monophosphate activated protein kinase (AMPK), a mediator of estradiol-induced apoptosis in long-term estrogen deprived breast cancer cells.
- Atypical hyperplasia of the breast--risk assessment and management options.
- Workshop on measuring estrogen exposure and metabolism: Summary of the presentations.
- Vaginal administration of estradiol: effects of dose, preparation and timing on plasma estradiol levels.
- Estrogen metabolites and breast cancer.
- Epigenetic Reprogramming of HOXC10 in Endocrine-Resistant Breast Cancer.
- Competency in Menopause Management: Whither Goest the Internist?
- Current and Evolving Approaches to Individualizing Estrogen Receptor-Based Therapy Approaches for Menopausal Women.
- Metabolic effects of oral versus transdermal 17β-estradiol (e2): a randomized clinical trial in girls with turner syndrome.
- Menopausal hormone therapy and breast cancer.
- Occult Breast Tumor Reservoir: Biological Properties and Clinical Significance.
- Inhibitory effects of a bazedoxifene/conjugated equine estrogen combination on human breast cancer cells in vitro.
- Effects of the Conjugated Equine Estrogen/Bazedoxifene Tissue-Selective Estrogen Complex (TSEC) on Mammary Gland and Breast Cancer in Mice.
- Estrogen receptor-dependent and independent mechanisms of breast cancer carcinogenesis.
- Insights into mentorship for endocrinologists.
- Modeling of the growth kinetics of occult breast tumors: role in interpretation of studies of prevention and menopausal hormone therapy.
- Atrofia vaginal.
- Vaginal atrophy.
- Estrogen stimulation of cell migration involves multiple signaling pathway interactions.
- Isolated and combined action of tamoxifen and metformin in wild-type, tamoxifen-resistant, and estrogen-deprived MCF-7 cells.
- "Dwarf" estrogen receptor in breast cancer and resistance to tamoxifen.
- Estrogen signals via an extra-nuclear pathway involving IGF-1R and EGFR in tamoxifen-sensitive and -resistant breast cancer cells.
- Mechanisms of resistance to structurally diverse antiestrogens differ under premenopausal and postmenopausal conditions: evidence from in vitro breast cancer cell models.
- Potential role of ultra-sensitive estradiol assays in estimating the risk of breast cancer and fractures.
- CYP1B1 is not a major determinant of the disposition of aromatase inhibitors in epithelial cells of invasive ductal carcinoma.
- Adaptation to estradiol deprivation causes up-regulation of growth factor pathways and hypersensitivity to estradiol in breast cancer cells.
- Innovative endocrinology of cancer. Preface.
- Histologic changes in the breast with menopausal hormone therapy use: correlation with breast density, estrogen receptor, progesterone receptor, and proliferation indi...
- Standardization of steroid hormone assays: why, how, and when?
- Estrogen signaling via a linear pathway involving insulin-like growth factor I receptor, matrix metalloproteinases, and epidermal growth factor receptor to activate mi...
- Superiority of gas chromatography/tandem mass spectrometry assay (GC/MS/MS) for estradiol for monitoring of aromatase inhibitor therapy.
- Effects of tetramethoxystilbene on hormone-resistant breast cancer cells: biological and biochemical mechanisms of action.
- Long-term treatment with tamoxifen facilitates translocation of estrogen receptor alpha out of the nucleus and enhances its interaction with EGFR in MCF-7 breast cance...
- Membrane initiated estrogen signaling in breast cancer.
- Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines.
- Farnesylthiosalicylic acid blocks mammalian target of rapamycin signaling in breast cancer cells.
- Estrogen rapid action via protein complex formation involving ERalpha and Src.
- Recombinant cell ultrasensitive bioassay for measurement of estrogens in postmenopausal women.
- Proceedings of the Fourth International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: conference summary statement.
- Tamoxifen versus aromatase inhibitors for breast cancer prevention.
- Farnesylthiosalicylic acid inhibits mammalian target of rapamycin (mTOR) activity both in cells and in vitro by promoting dissociation of the mTOR-raptor complex.
- The role of adapter protein Shc in estrogen non-genomic action.
- The novel Ras antagonist, farnesylthiosalicylate, suppresses growth of prostate cancer in vitro.
- The role of Shc and insulin-like growth factor 1 receptor in mediating the translocation of estrogen receptor alpha to the plasma membrane.
- Long-term exposure to tamoxifen induces hypersensitivity to estradiol.
- Proceedings of the Third International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: conference summary statement.
- Adaptive hypersensitivity to estrogen: mechanism for sequential responses to hormonal therapy in breast cancer.
- Risk of breast cancer with progestins: critical assessment of current data.
- Inhibition of aromatase: insights from recent studies.
- MICoA, a novel metastasis-associated protein 1 (MTA1) interacting protein coactivator, regulates estrogen receptor-alpha transactivation functions.
- Hot flashes: the old and the new, what is really true?
- Activation of the MAPK pathway enhances sensitivity of MCF-7 breast cancer cells to the mitogenic effect of estradiol.
- To block estrogen's synthesis or action: that is the question.
- Membrane association of estrogen receptor alpha mediates estrogen effect on MAPK activation.
- Treatment of urogenital atrophy with low-dose estradiol: preliminary results.
- Linkage of rapid estrogen action to MAPK activation by ERalpha-Shc association and Shc pathway activation.
- Induction of apoptosis in hormone refractory breast cancer: horizontal modulation is superior to vertical.
Schools
University Of Michigan Medical School
New York Presbyterian HospitalWeill Cornell Med Center
University Mich Hospital
University Wash
Doctors Specialties
- Internal Medicine
- Endocrinology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
- Elected Member
Education
-
University of Michigan Hospitals and Health Centers -
New York Presbyterian Hospital - Cornell Campus -
University of Michigan Medical School
Hospital
-
University of Virginia Medical Center
Drug Facts
| NPI NUMBER | 1417091281 | |
| NPPES Provider LastName | SANTEN | |
| NPPES Provider FirstName | RICHARD | |
| NPPES Provider ZIPCode | 22903 | |
| NPPES Provider State | VA | |
| Specialty Description | Internal Medicine | |
| Total Claim Count | 527.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1417091281 |
| Last Name Of The Provider | SANTEN |
| First Name Of The Provider | RICHARD |
| View All |
Similar Doctors
|
Dr. Alan C. Dalkin, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Mary Lee VanCe, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Anthony L. McCall, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
Dr. Eugene J. Barrett, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
Dr. Ross C. Buerlein, MD |
|
|
Dr. Sandhya Chhabra, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kara B. Hawkins, MD
This Doctor is OpenDoctor Recommended.
|